Skip to content
value.today

Tenax Therapeutics, Inc.

TENX
$86 Mmarket cap on Oct 29, 2026+1612.2% since Jan 2024
Compare
World rank
#19,330
Revenue
—
For year ending December-2025
Net income
$-53 M
SEC filing
Employees
14
As of December 31, 2025
SEC filing

Tenax Therapeutics, Inc. in brief

Tenax Therapeutics, Inc. is a listed company in the Biotechnology industry, based in Chapel Hill, North Carolina, USA. Its market value was $86 M on 29 October 2026, which makes it the 19,330th largest listed company in the world and the 3,600th largest in the USA on this site. It employs about 14 people and Christopher Thomas Giordano is its chief executive. Its shares trade under the symbol TENX (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Tenax Therapeutics, Inc.

Tenax Therapeutics is a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies. We employ a clinician-driven drug development approach, led by key opinion leaders and heart failure experts and informed by their clinical insights to precisely target disease pathophysiology. We are currently actively conducting the LEVEL and LEVEL-2 clinical trials to evaluate levosimendan as our prioritized product candidate and have deprioritized a Phase 3 clinical trial of imatinib, two drugs supported by promising evidence that they may significantly improve the lives of patients with pulmonary hypertension. Importantly, both levosimendan and imatinib have already been approved in other indications and prescribed around the world for more than 20 years, and we believe their mechanisms of action are uniquely suitable to target and treat pulmonary hypertension. We believe this derisked approach of using already-approved drugs that provide well-established safety profiles from millions of patients, combined with a development path led by preeminent cardiovascular and pulmonary hypertension experts, puts us in a strong position to deliver breakthrough cardiopulmonary therapies designed to improve patients’ functioning and quality of life.

From the company's annual report filed with the US SEC: read the report

Tenax Therapeutics, Inc. timeline

3 events, 1996–2014
  1. 1996
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2008
  4. ✎
    Renamed Oxygen Biotherapeutics, Inc.
    Formerly Synthetic Blood International Inc.
  5. 2014
  6. ✎
    Renamed Tenax Therapeutics, Inc.
    Formerly Oxygen Biotherapeutics, Inc..

Events of Tenax Therapeutics, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$23 M$46 M$69 M$92 M2020202120222023202420252026

World rank over time

▲ up 7,063 places since 2020
2020-01-01: #26436#26,43620202021-01-01: #22680#22,68020212022-01-07: #30406#30,40620222022-12-25: #32737#32,73720222023-07-30: #32516#32,51620232024-01-05: #32354#32,35420242026-03-08: #10553#10,55320262026-08-01: #18598#18,59820262026-10-13: #19502#19,50220262026-10-29: #19373#19,3732026

Rank in USA: #4,672 (Jan 2020) · #4,335 (Jan 2021) · #5,361 (Jan 2022) · #5,759 (Dec 2022) · #5,533 (Jul 2023) · #4,630 (Jan 2024) · #2,063 (Mar 2026) · #3,626 (Aug 2026) · #3,595 (Oct 2026) · #3,603 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
0.9×
Free cash flow yield
-13.3%
Net margin
—
Operating margin
—
Return on equity
-54.2%
Liabilities / assets
6.9%
Revenue growth
-68.8%
R&D / revenue
13320.0%
Profit per employee
$-3.8 M

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue —, net income $-14M—FY18Fiscal year ending Dec 2019: revenue —, net income $-8M—FY19Fiscal year ending Dec 2020: revenue —, net income $-10M—FY20Fiscal year ending Dec 2021: revenue —, net income $-32M—FY21Fiscal year ending Dec 2022: revenue —, net income $11M—FY22Fiscal year ending Dec 2023: revenue —, net income $-8M—FY23Fiscal year ending Dec 2024: revenue —, net income $-18M—FY24Fiscal year ending Dec 2025: revenue —, net income $-53M—FY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025——$-56M$-53M—
Dec 2024——$-19M$-18M—
Dec 2023——$-8M$-8M—
Dec 2022——$11M$11M—
Dec 2021——$-33M$-32M—
Dec 2020——$10M$-10M—
Dec 2019——$-9M$-8M—
Dec 2018——$-7M$-14M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-36M——$-1.34—
Dec 2024$-15M——$-1.15—
Dec 2023$-6M——$-31.04—
Dec 2022$-11M$0M$-11M——
Dec 2021$-11M$0M$-11M$-1.58—
Dec 2020$-9M$0M$-9M$-0.95—
Dec 2019$-8M$0M$-8M$-1.35—
Dec 2018$-6M$0M$-6M$-9.04—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue —, net income $-6M—Dec ’24Three months to Mar 2025: revenue —, net income $-10M—Mar ’25Three months to Jun 2025: revenue —, net income $-11M—Jun ’25Three months to Sep 2025: revenue —, net income $-16M—Sep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-16M—Dec ’25Three months to Mar 2026: revenue —, net income $-16M—Mar ’26Three months to Jun 2026: revenue —, net income $-18M—Jun ’26Three months to Sep 2026: revenue —, net income $-17M—Sep ’26

Latest quarter to Sep 2026: revenue —, net income $-17M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Tenax Therapeutics, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
—
Operating income
$-56 M
Net income
$-53 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$104 M
Total liabilities
$7 M
Total equity
$97 M

As of December-2025

Top 100 institutional investors in Tenax Therapeutics, Inc.#

As of Sep 30, 2026
106 institutions held 32.0 M shares (about 70.2% of the shares outstanding) on Sep 30, 2026. The ten largest hold 47.2%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Tenax Therapeutics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1ADAR1 Capital Management, LLC6,524,151+6,303,689 (+2859.31%)14.33%$12 MNov 16, 2026
2BlackRock, Inc.2,805,496+1,077,508 (+62.36%)6.16%$5 MNov 13, 2026
3Vivo Capital, LLC2,500,0000 (0.00%)5.49%$5 MNov 13, 2026
4Sphera Funds Management LTD.2,315,696+2,195,496 (+1826.54%)5.09%$4 MNov 16, 2026
5Marshall Wace, LLP1,779,564+1,193,986 (+203.90%)3.91%$3 MNov 13, 2026
6Millennium Management LLC1,362,730+486,500 (+55.52%)2.99%$3 MNov 16, 2026
7AQR Capital Management LLC1,252,703New2.75%$2 MNov 16, 2026
8Vanguard Capital Management LLC1,131,973-15,148 (-1.32%)2.49%$2 MNov 13, 2026
9Morgan Stanley942,937+510,717 (+118.16%)2.07%$2 MNov 13, 2026
10Geode Capital Management, LLC864,596+225,059 (+35.19%)1.90%$2 MNov 6, 2026
11Jane Street Group, LLC689,312+422,656 (+158.50%)1.51%$1 MNov 12, 2026
12Goldman Sachs Group Inc627,023+352,077 (+128.05%)1.38%$1 MNov 16, 2026
13Stonepine Capital Management, LLC588,000-72,000 (-10.91%)1.29%$1 MNov 13, 2026
14Braidwell LP584,4120 (0.00%)1.28%$1 MNov 16, 2026
15Wellington Management Group LLP555,995+460,482 (+482.11%)1.22%$1 MNov 16, 2026
16State Street Corp535,410+24,596 (+4.82%)1.18%$1 MNov 12, 2026
17FMR LLC533,217-3,409,156 (-86.47%)1.17%$1 MNov 10, 2026
18Caitong International Asset Management Co., Ltd489,906+489,756 (+326504.00%)1.08%$1 MOct 29, 2026
19Susquehanna International Group, LLP428,063+138,899 (+48.03%)0.94%$1 MNov 16, 2026
20Adage Capital Partners GP, L.L.C.409,733-130,393 (-24.14%)0.90%$1 MNov 16, 2026
21Balyasny Asset Management L.P.369,587New0.81%$1 MNov 16, 2026
22Qube Research & Technologies Ltd280,621-149,272 (-34.72%)0.62%$1 MNov 13, 2026
23UBS Group AG274,223+176,080 (+179.41%)0.60%$1 MNov 10, 2026
24Prudential Financial Inc249,695New0.55%$0 MNov 16, 2026
25Vanguard Portfolio Management LLC247,776+78,935 (+46.75%)0.54%$0 MNov 13, 2026
Show all 100: investors 26 to 100
Institutional investors 26 to 100 in Tenax Therapeutics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Quadrature Capital Ltd238,886New0.52%$0 MNov 13, 2026
27Northern Trust Corp234,818+35,684 (+17.92%)0.52%$0 MNov 16, 2026
28Ensign Peak Advisors, Inc234,205+57,316 (+32.40%)0.51%$0 MNov 12, 2026
29Nuveen, LLC215,359+54,172 (+33.61%)0.47%$0 MNov 10, 2026
30Vanguard Fiduciary Trust Co212,850+55,808 (+35.54%)0.47%$0 MNov 13, 2026
31Walleye Capital LLC204,144+98,907 (+93.99%)0.45%$0 MNov 13, 2026
32Citigroup Inc175,348+163,725 (+1408.63%)0.39%$0 MNov 4, 2026
33LMR Partners LLP150,489New0.33%$0 MNov 16, 2026
34Ikarian Capital, LLC136,648-650,952 (-82.65%)0.30%$0 MNov 16, 2026
35Barclays PLC124,205+116,151 (+1442.15%)0.27%$0 MNov 6, 2026
36Jones Hill Capital LP122,169New0.27%$0 MNov 13, 2026
37Engineers Gate Manager LP99,996New0.22%$0 MNov 16, 2026
38Caption Management, LLC93,005-161,995 (-63.53%)0.20%$0 MNov 16, 2026
39Charles Schwab Investment Management Inc89,743+28,569 (+46.70%)0.20%$0 MNov 16, 2026
40Bank of New York Mellon Corp84,079-241,217 (-74.15%)0.18%$0 MNov 5, 2026
41Dimensional Fund Advisors LP74,577-178,941 (-70.58%)0.16%$0 MNov 4, 2026
42Gsa Capital Partners LLP72,503New0.16%$0 MNov 16, 2026
43Verdad Advisers, LP62,127-61,047 (-49.56%)0.14%$0 MNov 16, 2026
44Axq Capital, LP61,424New0.13%$0 MNov 12, 2026
45Bridgeway Capital Management, LLC59,9000 (0.00%)0.13%$0 MNov 16, 2026
46Rangeley Capital, LLC55,000New0.12%$0 MNov 16, 2026
47State of Alaska, Department of Revenue50,000New0.11%$0 MOct 15, 2026
48Alps Advisors Inc49,225+22,301 (+82.83%)0.11%$0 MNov 3, 2026
49Panagora Asset Management Inc44,280-111,782 (-71.63%)0.10%$0 MNov 12, 2026
50XTX Topco Ltd40,919-72,848 (-64.03%)0.09%$0 MNov 16, 2026
51Creek Drive Management Group LLC38,000-36,000 (-48.65%)0.08%$0 MNov 10, 2026
52Deutsche Bank AG\35,381+10,824 (+44.08%)0.08%$0 MNov 6, 2026
53Simplex Trading, LLC32,403New0.07%$0 MNov 4, 2026
54Rhumbline Advisers30,617-674 (-2.15%)0.07%$0 MNov 10, 2026
55Bank Of America Corp /de/30,189-106,239 (-77.87%)0.07%$0 MNov 16, 2026
56Jpmorgan Chase & Co28,208+17,697 (+168.37%)0.06%$0 MNov 12, 2026
57Boothbay Fund Management, LLC27,464-283,623 (-91.17%)0.06%$0 MNov 16, 2026
58BVF Inc/il25,000-314,549 (-92.64%)0.05%$0 MNov 16, 2026
59Wells Fargo & Company/mn24,139+3,055 (+14.49%)0.05%$0 MNov 16, 2026
60Two Sigma Investments, LP24,027-329,363 (-93.20%)0.05%$0 MNov 16, 2026
61Russell Investments Group, Ltd.22,667+20,616 (+1005.17%)0.05%$0 MNov 6, 2026
62Vanguard Personalized Indexing Management, LLC21,144New0.05%$0 MNov 16, 2026
63Price T Rowe Associates Inc /MD/20,670-586,990 (-96.60%)0.05%$0 MNov 16, 2026
64Alliancebernstein L.P.19,9000 (0.00%)0.04%$0 MNov 16, 2026
65MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.17,481+5,937 (+51.43%)0.04%$0 MNov 16, 2026
66WINTON GROUP Ltd16,900New0.04%$0 MNov 12, 2026
67Gabelli Funds LLC15,000New0.03%$0 MNov 12, 2026
68Invesco Ltd.14,301+1,205 (+9.20%)0.03%$0 MNov 12, 2026
69Verition Fund Management LLC13,5890 (0.00%)0.03%$0 MNov 13, 2026
70BNP Paribas Financial Markets12,510-35,325 (-73.85%)0.03%$0 MNov 12, 2026
71Corient Private Wealth LP12,3880 (0.00%)0.03%$0 MNov 16, 2026
72Letko, Brosseau & Associates Inc10,6500 (0.00%)0.02%$0 MNov 6, 2026
73Callan Family Office, LLC10,453New0.02%$0 MNov 13, 2026
74Mendel Money Management10,300New0.02%$0 MNov 2, 2026
75Centiva Capital, LP10,211New0.02%$0 MNov 13, 2026
76SEI Investments Co10,1100 (0.00%)0.02%$0 MNov 10, 2026
77Vanguard Global Advisers, LLC10,015-2,095 (-17.30%)0.02%$0 MNov 13, 2026
78IFG Advisors, LLC10,000New0.02%$0 MOct 15, 2026
79Global Retirement Partners, LLC9,335New0.02%$0 MNov 10, 2026
80New York State Common Retirement Fund8,8000 (0.00%)0.02%$0 MNov 17, 2026
81Pinnacle Wealth Planning Services, Inc.8,103New0.02%$0 MOct 27, 2026
82Police & Firemen's Retirement System of New Jersey7,4250 (0.00%)0.02%$0 MNov 9, 2026
83PNC Financial Services Group, Inc.6,066New0.01%$0 MNov 6, 2026
84Tower Research Capital LLC (TRC)5,927+3,619 (+156.80%)0.01%$0 MNov 16, 2026
85Strs Ohio4,9000 (0.00%)0.01%$0 MOct 30, 2026
86Federated Hermes, Inc.4,579New0.01%$0 MNov 12, 2026
87GAMMA Investing LLC2,591New0.01%$0 MOct 8, 2026
88Legal & General Group Plc2,4420 (0.00%)0.01%$0 MNov 16, 2026
89Bradley & Co. Private Wealth Management, LLC2,325New0.01%$0 MOct 23, 2026
90Ameritas Investment Partners, Inc.2,2850 (0.00%)0.01%$0 MNov 13, 2026
91Jones Financial Companies Lllp2,090+2,089 (+208900.00%)0.00%$0 MNov 13, 2026
92Royal Bank Of Canada1,982+1,206 (+155.41%)0.00%$0 MNov 16, 2026
93EverSource Wealth Advisors, LLC1,877New0.00%$0 MNov 4, 2026
94Parkside Financial Bank & Trust1,520New0.00%$0 MOct 27, 2026
95Sterling Capital Management LLC712+205 (+40.43%)0.00%$0 MOct 22, 2026
96Arax Advisory Partners407New0.00%$0 MNov 12, 2026
97SBI Securities Co., Ltd.388+331 (+580.70%)0.00%$0 MOct 22, 2026
98UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC378New0.00%$0 MNov 16, 2026
99California State Teachers Retirement System3470 (0.00%)0.00%$0 MNov 13, 2026
100Fortitude Family Office, LLC343New0.00%$0 MOct 14, 2026

All 106 institutional investors, with who bought and sold →

Mutual funds holding Tenax Therapeutics, Inc.#

82 funds hold shares worth $81 M. Since their previous reports 73 added shares and 4 sold, buying $32 M net.
Mutual funds holding Tenax Therapeutics, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.852,259$12 M17.4%<0.01%+339%Jun 30, 2026
🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors648,782$9 M13.3%0.01%newJun 30, 2026
🇺🇸 T. Rowe Price Health Sciences Fund, Inc.T. Rowe Price Associates, Inc.445,976$6 M9.1%0.05%−82%Jun 30, 2026
🇺🇸 Fidelity Advisor Biotechnology FundFidelity Management & Research Company LLC445,100$6 M9.1%0.28%+38%Jul 31, 2026
🇺🇸 Nuveen Quant Small Cap Equity FundTeachers Advisors, LLC432,200$6 M8.8%0.15%newJul 31, 2026
🇺🇸 Fidelity Small Cap Discovery FundFidelity Management & Research Company LLC335,016$5 M6.9%0.20%newJul 31, 2026
🇺🇸 Fidelity Series Small Cap Discovery FundFidelity Management & Research Company LLC299,100$4 M6.1%0.21%newJul 31, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.277,850$4 M5.7%<0.01%+333%Jun 30, 2026
🇺🇸 Fidelity Series Small Cap Core FundFidelity Management & Research Company LLC282,400$4 M5.8%0.25%newJul 31, 2026
🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC275,703$4 M5.6%0.01%newJul 31, 2026
🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors228,271$3 M4.7%0.02%newJun 30, 2026
🇺🇸 BNY Mellon Small/Mid Cap Growth FundBNY Mellon Investment Funds I125,362$2 M2.6%0.21%newJun 30, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors83,907$1 M1.7%0.08%newJun 30, 2026
🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP68,684$1 M1.4%<0.01%+16%Jul 31, 2026
🇺🇸 Strategic Advisers Fidelity U.S. Total Stock FundStrategic Advisers LLC76,941$1 M1.6%<0.01%newMay 31, 2026
🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc.61,174$1 M1.3%0.01%newJul 31, 2026
🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC57,630$1 M1.2%0.03%newJul 31, 2026
🇺🇸 U.S. Micro Cap PortfolioDimensional Fund Advisors LP53,228$1 M1.1%<0.01%+127%Jul 31, 2026
🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC46,654$1 M0.95%0.01%newJun 30, 2026
🇺🇸 College Retirement Equities Fund - Total Global Stock AccountTIAA-CREF Investment Management, LLC45,100$1 M0.92%<0.01%newJun 30, 2026
🇺🇸 T. Rowe Price Health Sciences PortfolioT. Rowe Price Associates, Inc.43,036$1 M0.88%0.08%−72%Jun 30, 2026
🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC35,209$1 M0.72%0.02%newJun 30, 2026
🇺🇸 PGIM Quant Solutions Large-Cap Core FundPGIM INVESTMENTS LLC35,100$0 M0.72%0.05%newJul 31, 2026
🇺🇸 U.S. Small Cap PortfolioDimensional Fund Advisors LP34,147$0 M0.70%<0.01%+169%Jul 31, 2026
🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC33,669$0 M0.69%0.01%newJul 31, 2026
🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC27,186$0 M0.56%0.01%newJun 30, 2026
🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP27,926$0 M0.57%<0.01%+103%Jul 31, 2026
🇺🇸 Nuveen Equity Index FundTeachers Advisors, LLC27,208$0 M0.56%<0.01%newJul 31, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC28,375$0 M0.58%<0.01%−0.8%May 31, 2026
🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation18,400$0 M0.38%0.01%newJun 30, 2026
🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc.12,955$0 M0.26%0.01%newJun 30, 2026
🇺🇸 Acuitas US Microcap FundAcuitas Investments, LLC12,618$0 M0.26%0.16%—Jun 30, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.11,936$0 M0.24%<0.01%newJun 30, 2026
🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC11,967$0 M0.24%0.01%newJul 31, 2026
🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC9,950$0 M0.20%<0.01%newJun 30, 2026
🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC9,950$0 M0.20%<0.01%newJun 30, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC11,937$0 M0.24%<0.01%+482%May 31, 2026
🇺🇸 Health Sciences TrustJohn Hancock Variable Trust Advisers LLC9,723$0 M0.20%0.06%+709%Jun 30, 2026
🇺🇸 EQ/T.Rowe Price Health Sciences PortfolioEquitable Investment Management Group, LLC8,857$0 M0.18%0.07%+952%Jun 30, 2026
🇺🇸 U.S. Vector Equity PortfolioDimensional Fund Advisors LP9,046$0 M0.18%<0.01%newJul 31, 2026
🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC8,471$0 M0.17%0.01%newJun 30, 2026
🇺🇸 BNY Mellon Small Cap Multi-Strategy FundBNY Mellon Investment Adviser, Inc.10,321$0 M0.21%0.09%newMay 31, 2026
🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc.7,400$0 M0.15%<0.01%newJun 30, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC8,940$0 M0.18%<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC8,907$0 M0.18%<0.01%−10%May 31, 2026
🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC7,153$0 M0.15%0.01%newJun 30, 2026
🇺🇸 Diversified Equity Alpha Master PortfolioBlackRock Fund Advisors6,030$0 M0.12%<0.01%newJun 30, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC5,649$0 M0.12%0.04%newJun 30, 2026
🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC5,569$0 M0.11%<0.01%newJun 30, 2026
🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS5,553$0 M0.11%0.01%newJun 30, 2026
🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC5,427$0 M0.11%0.01%newJun 30, 2026
🇺🇸 Dimensional US Core Equity Market ETFDimensional Fund Advisors LP5,403$0 M0.11%<0.01%+140%Jul 31, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.5,076$0 M0.10%<0.01%no changeJun 30, 2026
🇺🇸 U.S. Core Equity 1 PortfolioDimensional Fund Advisors LP4,385$0 M0.09%<0.01%+55%Jul 31, 2026
🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC4,364$0 M0.09%<0.01%newJul 31, 2026
🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc.3,954$0 M0.08%0.01%newJun 30, 2026
🇺🇸 1290 VT Small Cap Value PortfolioEquitable Investment Management Group, LLC3,885$0 M0.08%0.01%newJun 30, 2026
🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc.3,797$0 M0.08%0.01%newJun 30, 2026
🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC3,371$0 M0.07%0.01%newJun 30, 2026
🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC3,051$0 M0.06%0.01%newJun 30, 2026
🇺🇸 Dimensional U.S. Equity Market ETFDimensional Fund Advisors LP3,160$0 M0.06%<0.01%newJul 31, 2026
🇺🇸 iShares Total U.S. Stock Market Index FundBlackRock Advisors, LLC3,030$0 M0.06%<0.01%newJul 31, 2026
🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC2,948$0 M0.06%0.01%newJul 31, 2026
🇺🇸 U.S. Sustainability Core 1 PortfolioDimensional Fund Advisors LP2,751$0 M0.06%<0.01%no changeJul 31, 2026
🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc.2,622$0 M0.05%<0.01%newJul 31, 2026
🇺🇸 Dimensional US Core Equity 1 ETFDimensional Fund Advisors LP2,603$0 M0.05%<0.01%+174%Jul 31, 2026
🇺🇸 JNL/DFA U.S. Small Cap FundJackson National Asset Management, LLC2,345$0 M0.05%<0.01%+43%Jun 30, 2026
🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management2,285$0 M0.05%0.01%newJun 30, 2026
🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS2,223$0 M0.05%0.01%newJul 31, 2026
🇺🇸 PD Small-Cap Value Index PortfolioPacific Life Fund Advisors LLC2,064$0 M0.04%0.02%newJun 30, 2026
🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC2,009$0 M0.04%0.01%newJun 30, 2026
🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC1,811$0 M0.04%0.01%newJun 30, 2026
🇺🇸 SmallCap Value Fund IIPrincipal Global Investors, LLC1,643$0 M0.03%<0.01%newJul 31, 2026
🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC1,180$0 M0.02%<0.01%newJun 30, 2026
🇺🇸 Small-Cap Equity PortfolioPacific Life Fund Advisors LLC1,171$0 M0.02%<0.01%newJun 30, 2026
🇺🇸 SA U.S. Small Company FundFocus Advisor Solutions, LLC1,076$0 M0.02%<0.01%newJun 30, 2026
🇺🇸 Nationwide Fundamental All Cap Equity PortfolioNATIONWIDE FUND ADVISORS1,099$0 M0.02%<0.01%newJul 31, 2026
🇺🇸 U.S. Core Equity 2 PortfolioDimensional Fund Advisors LP1,090$0 M0.02%<0.01%no changeJul 31, 2026
🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC880$0 M0.02%<0.01%newJun 30, 2026
🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC800$0 M0.02%<0.01%newJun 30, 2026
🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc.636$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC335$0 M<0.01%<0.01%newJun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 82 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Tenax Therapeutics, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$6.5 M
20 purchases, 6 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$6.5 M
open market only
Insiders on file
21
since
$2.5 M$0Aug 2024: bought $0 (2 trades), sold $0 (0 trades)Aug 24Nov 2025: bought $93 K (8 trades), sold $0 (0 trades)NovDec 2025: bought $96 K (5 trades), sold $0 (0 trades)DecAug 2026: bought $2.5 M (4 trades), sold $0 (0 trades)AugSep 2026: bought $2.4 M (7 trades), sold $0 (0 trades)SepOct 2026: bought $1.5 M (3 trades), sold $0 (0 trades)Oct
Bought (open market)Sold (open market)Hover a month for the totals
Tenax Therapeutics, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed ADAR1 Capital Management, LLC10% ownerBuyindirect+331,979$1.659$551 K7.45 MForm 4
filed ADAR1 Capital Management, LLC10% ownerBuyindirect+254,342$1.595$406 K7.12 MForm 4
filed ADAR1 Capital Management, LLC10% ownerBuyindirect+336,528$1.507$507 K6.86 MForm 4
filed Declan DooganDirectorBuy+53,000$1.920$102 K55,274Form 4
filed Christopher Thomas GiordanoCEO, DirectorBuy+4,850$1.820$9 K22,174Form 4
filed Thomas R. Staab IIChief Financial OfficerBuy+5,675$1.940$11 K15,675Form 4
filed Christopher Thomas GiordanoCEO, DirectorBuy+6,000$1.880$11 K17,324Form 4
filed ADAR1 Capital Management, LLC10% ownerBuyindirect+900,000$1.780$1.6 M6.52 MForm 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Tenax Therapeutics, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
5.8 M
62.5% of shares · 3.17 days to cover
Shares sold short, last 24 reportsAll stocks →

Trading halts

  • 2025-06-20 17:39 UTC, code LUDP, resumed 17:44 UTC

Fails to deliver

  • : 3,230 shares at $1.88
  • : 292 shares at $1.83
  • : 2,180 shares at $1.91
  • : 350 shares at $1.93
  • : 1,827 shares at $1.98

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Tenax Therapeutics, Inc. scorecard#

Passes 2 of the 12 checks that could be worked out: strongest in valuation (1 of 4), weakest in profitability (0 of 3). Fiscal year 2025; market cap of Oct 29, 2026.

  • Valuation1 of 4
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✓Price to book below its peers' median0.9×Price to book 0.9× against Biotechnology's median of 2.9×.
    • –Price to sales below its peers' medianNo Price to sales on file.
    • ✗Free cash flow yield above 5%-13.3%Free cash flow is -13.3% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth0 of 2
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-1.34 vs -1.15Diluted EPS -1.34 in fiscal 2025 against -1.15 the year before (report's currency).
    • ✗Net income higher than five years earlier-$53 M-$53 M in fiscal 2025 against -$10 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$53 MNet income -$53 M in fiscal 2025.
    • ✗Profitable in each of the last five years1 of 5Profitable in 1 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-55.6%-55.6% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 2
    • ✓Short-term assets cover short-term liabilities14.6×Current ratio 14.56 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year156.8%Diluted shares up 156.8% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Tenax Therapeutics, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Tenax Therapeutics, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue00———————0
Cost of revenue—————————0
Gross profit—————————0
Research and development33133.2r5.4254.63.51.23.513
Selling, general and administrative————7.65.35.15.75.76.2
General and administrative246.85.0r5.77.6—————
Operating expenses56198.2r11339.98.66.99.253
Operating income−56−19−8.2r11r−33r9.9r−8.6−6.9−9.2−53
Interest expense and finance costs00.00.0r0.00.00.00——0
Net interest income————0.00.0————
Other non-operating income (expense)−0.00.00.1r−0.0—0.00.20.10.40.8
Income tax000000000−8.0
Net income including minority interests−53−18−7.7r−11−32r9.9————
Net income attributable to shareholders−53−18−7.7r11r−32−9.9−8.4−14−8.8−44
Earnings per share, basic-1.34-1.15-31.04—-1.58-0.95r-1.35-9.04-6.27-31.24r
Earnings per share, diluted-1.34-1.15-31.04—-1.58-0.95r-1.35-9.04-6.27-31.24r
Shares, weighted average (basic)39150.2———————
Shares, weighted average (diluted)39150.2—2110r6.21.61.41.4r
Balance sheet
Cash and cash equivalents98959.82.15.66.34.9121.610.0
Short-term investments————00.50.50.56.13.3
Receivables———————00.10.1
Other current assets1.00.1r0.3r0.30—————
Current assets1049712r3.25.76.86.2138.114
Property, plant and equipment——00.00.00.00.00.00.00.0
Right-of-use (leased) assets——00.20.30.10.20——
Goodwill—————————0
Other intangible assets—————————0
Total assets1049712r3.46.06.96.4139.923
Accounts payable6.03.22.1r0.40.90.81.70.70.60.7
Current liabilities7.24.73.6r1.81.62.12.51.61.06.2
Lease liabilities (non-current)——00.10.200.10——
Non-current liabilities——00.10.20.10.1———
Total liabilities7.24.73.6r1.91.72.22.61.61.06.2
Retained earnings−367−315−297r−290−278−246−236−228−213−205
Shareholders' equity97928.1r1.5r4.24.63.8128.917
Total liabilities and equity1049712r3.46.06.96.4139.923
Shares outstanding9.33.40.30.0r1.3r136.73.81.41.4r
Cash-flow statement
Depreciation and amortization—00.0r0.00.00.00.00.00.00.0
Share-based compensation191.10.2———00.20.10.0
Cash from operating activities−36−15−5.9r−11r−11−9.3−7.6−5.5−12−16
Capital expenditure———−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Intangible assets bought—————————0
Cash from investing activities—00.0r−0.00.50.0−0.07.43.722
Debt repaid————−0.2—————
Shares issued—————8.70———
Cash from financing activities3910014r7.9r9.7110.18.900
Change in cash—————1.3−7.511−8.46.3
Report10-K10-K10-K10-K10-K10-K10-K/A10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Executive pay at Tenax Therapeutics, Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$8.1 M
Christopher T. Giordano
Other top executives, average
$1.9 M
the CEO earned 4.3× this
$100 invested is now
$1
Tenax Therapeutics, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Christopher T. Giordano$8.1 M$21.7 M$1.9 M$1
2024Christopher Thomas Giordano$7.4 M$7.7 M$1.7 M$0
2023Christopher Thomas Giordano$645 K$516 K$324 K$1

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Tenax Therapeutics, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Directors and officers 5 · Material agreement 3 · Unregistered share sale 1 · Bylaws or fiscal year changed 1 · Shareholder vote 3 · Results announced 10

Tenax Therapeutics, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Results announced8-K
Material agreement8-K
Directors and officers8-K
Shareholder vote8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Material agreement8-K
Results announced8-K
Bylaws or fiscal year changedShareholder vote8-K
Results announced8-K
Results announced8-K
Material agreementUnregistered share sale8-K
Directors and officers8-K
Results announced8-K
Directors and officersShareholder vote8-K
Results announced8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 5, 2026

Acquisitions and funding#

1 private funding rounds before listing

Private share sales · funding history

Private share sales of Tenax Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Aug 2024$100 MPrivate placement after listing$50 to $250 million24equity, optionsSEC
May 2022$8 MPrivate placement after listing$2 to $10 million1optionsSEC
Jul 2021$10 MPrivate placement after listing$10 to $50 million1optionsSEC
Jul 2020$5 MPrivate placement after listing$2 to $10 million1optionsSEC
Nov 2013$7 MPrivate placement after listing$2 to $10 million4equitySEC
Aug 2013$5 MPrivate placement after listing$2 to $10 million1equity, optionsSEC
Feb 2013$2 MPrivate placement after listing$2 to $10 million2equity, optionsSEC
Jun 2009$5 MNo. 1$2 to $10 million2equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

How Tenax Therapeutics, Inc. compares in Biotechnology

  • Market cap$86 M · higher than 33% of 726
  • Revenue growth-68.8% · higher than 11% of 438
  • Price / book0.9× · lower than 82% of 534
  • FCF yield-13.3% · higher than 51% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Tenax Therapeutics, Inc.🇺🇸$86 M——-68.8%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 29, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of December 31, 2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report, GLEIF register; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Tenax Therapeutics, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Tenax Therapeutics, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Tenax Therapeutics, Inc.? Suggest a correction